How'd you fix Cedar's revenue issues in 2026?

!How'd you fix Cedar's revenue issues in 2026?

Direct Answer

!How'd you fix Cedar's revenue issues in 2026?

Cedar's revenue fix in 2026 is surgical: (1) Abandon the "one-stop RCM" myth and become best-of-breed patient-payment orchestrator for health systems already locked into Waystar/Medidata/Epic—sell the integration, not the platform; (2) Flip from 5–10 year enterprise sales cycles to SMB/mid-market urgent-care and DSOs (Dental Service Organizations) with 6–12 month close cycles and immediate cash-flow relief; (3) Pivot the AI bill-explainer from commodity UX feature to backend B2B2C licensing play—white-label to insurers (Humana, UnitedHealth) who want member-engagement stickiness, 3–5x margin expansion per license.

What's Actually Broken

• Hospital-system procurement death-march: Cedar's core bet was replacing Waystar/Phreesia at large health systems. But Waystar is consolidating (bought Emdeon, Kareo, Navicure, point solutions)—switching costs for a 500-bed hospital are $5M+ and 18 months. Cedar's TAM is vanishing while competitors entrench.
• AI bill-explainer commoditization: Cedar's natural-language bill-summary feature is now baseline expectation. Phreesia, Waystar, and every patient-engagement vendor shipped parity tech. Selling it as differentiation is dead.
• 2021 valuation overhang + layoffs: Cedar raised at $3.2B (2021 peak); Series C at $1.3B (2023 believed). Founders took significant carry; the market reset to $500M–$800M range (implied ~$100–150M ARR, not the $200M+ they hoped). Burn is real; 2024 layoffs signal internal forecasting miss.
• Competitor integration moats: Waystar API is now standard in Epic, Cerner, Athenahealth. Phreesia owns the patient-visit touchpoint. Cedar is sandwiched as a replacement nobody wants to rip-and-replace.
• RCM expansion friction: Cedar's push into insurance-side claims and denial management is a decade behind Optum/DRG. The team lacks payer-side credibility and payer economics are cut-throat (razor-thin margins, SaaS churn 20%+).
• Sales-org scaling burnout: Enterprise health-system sales is a 18–36 month cycle with 5–7 stakeholders per deal. Cedar's payroll burn for a 50-person sales org targeting $200M ARR means path to profitability requires flipping to high-velocity segment.

2026 Fix Playbook

1. Segment exit: Abandon enterprise health-system RCM consolidation.

• Stop competing with Waystar on Waystar's turf. Surrender the "replace your RCM" story.
• Redeploy sales team to SMB urgent care ($10M–$100M revenue; 20–40 locations), DSOs (dental chains expanding to multi-unit franchises), and independent imaging centers.
• Close ratio in these segments 3–5x higher; sales cycle 6–12 months vs. 24+ months. Cash-flow inflection by Q3 2026.

1. Patient-pay as integration layer (not platform).

• Reposition Cedar as "patient financial experience" SaaS that sits atop legacy RCMs.
• Offer deep Waystar/Medidata/Epic connectors with 1–2 week implementations (vs. 6-month "rip-and-replace").
• Sell to health systems as a point-solution for reducing patient-payment friction + bad-debt write-off. $50K–$200K ACV instead of $2M+.
• Use Bridge Group playbooks for SMB packaging and Pavilion for sales-motion training.

1. AI bill-explainer → B2B2C licensing.

• Stop bundling natural-language bill summaries as a patient UX feature.
• White-label the NLP engine to health plans (Humana, UnitedHealth, Aetna) as "member engagement AI."
• Health plans want member stickiness and claim-clarity adoption; they'll pay $2–5M annually per plan for 100+ carriers.
• 15–20 health-plan licenses = $30–100M recurring revenue, gross margin 70%+ (no patient support burden).

1. Affiliate-payment network expansion (Klue for competitive intelligence).

• Phreesia and Waystar own point-of-service; Cedar can own the backend clearing network.
• Partner with PayFacs (Stripe, Square, Paylocity) to white-label Cedar's ACH/card/financing orchestration.
• Penetrate the SMB+DSO segment with 0% integration lift (Stripe Connect model).
• Margin upside: 0.5–1% take-rate on $500M+ payment volume = $2.5–5M ARR by 2027.

1. Revenue-cycle insights as SaaS (Force Management competitive sales framework).

• Flip the "AI bill-explainer" narrative: Cedar has 10+ years of health-system payment-behavior data.
• License aggregated, anonymized revenue-cycle benchmarking to hospital CFOs and imaging centers.
• "Your denial rate is 8.2%; peer median is 6.1%. Here's why" → $25K–$100K annual report subscriptions.
• Low CAC (content + LinkedIn); high margins. 500 subscribers = $12.5M–$50M ARR.

1. Denials automation via Revspringxor Optum partnership.

• Cedar's patient-payment data is upstream of the denial-management funnel.
• License pre-denial-flagging to Revspring or Optum's Denials Intelligence as OEM component.
• Revspring pays licensing fees for Cedar's early-warning signals; Cedar gets revenue without building full denials platform.
• $10M+ ARR from single strategic OEM if executed.

1. Aggressive 2026 M&A target: Acquire one DSO-focused RCM player or imaging-center PayFac.

• If Cedar has $100M+ cash, buy a $20–30M revenue player (Athena, CarePayment, Instamed) to own SMB segment entirely.
• 1.5–2x EBITDA purchase (~$60–80M) accelerates SMB TAM and avoids competitive feature-parity race.
• Integrate cash-flow playbooks + patient-payment tech into acquired product; 12-month payback.

Table

Mermaid

FAQ

Why should Cedar abandon enterprise health-system RCM consolidation? Cedar's core bet was replacing Waystar and Phreesia at large health systems, but Waystar is consolidating (it bought Emdeon, Kareo, and Navicure) and switching a 500-bed hospital costs $5M+ and 18 months. The TAM is vanishing while competitors entrench. The plan surrenders the "replace your RCM" story and redeploys sales to faster-closing segments.

Which segments should Cedar pivot to instead? The plan moves sales to SMB urgent care ($10M–$100M revenue, 20–40 locations), DSOs (dental chains expanding to multi-unit franchises), and independent imaging centers. Close ratios in these segments are 3–5x higher with 6–12 month sales cycles versus 24+ months for enterprise. That targets cash-flow inflection by Q3 2026.

How does repositioning Cedar as an integration layer change its ACV? Instead of a rip-and-replace platform, Cedar becomes a "patient financial experience" SaaS that sits atop legacy RCMs with deep Waystar, Medidata, and Epic connectors and 1–2 week implementations. This drops the ACV from $2M+ to $50K–$200K but competes on UX rather than feature-parity. It uses Bridge Group playbooks for SMB packaging and Pavilion for sales-motion training.

What is the B2B2C licensing play for the AI bill-explainer? The natural-language bill-summary feature is now commoditized, so the plan stops bundling it as a patient UX feature and white-labels the NLP engine to health plans like Humana, UnitedHealth, and Aetna as "member engagement AI." Plans would pay $2–5M annually each, and 15–20 licenses yield $30–100M in recurring revenue at 70%+ gross margin. There's no patient-support burden at that layer.

How would Cedar monetize its revenue-cycle data as a SaaS product? Cedar has 10+ years of health-system payment-behavior data, which it can license as anonymized revenue-cycle benchmarking to hospital CFOs and imaging centers. The pitch is concrete: "Your denial rate is 8.2%; peer median is 6.1%. Here's why," sold as $25K–$100K annual report subscriptions. With low CAC from content and LinkedIn, 500 subscribers would equal $12.5M–$50M ARR.

Bottom Line

Cedar's enterprise RCM story is dead; survival is ruthless segment pivot to high-velocity SMB + health-plan licensing + data-insights SaaS—three independent revenue streams that defend against Waystar's consolidation moat.

TAGS

cedar, healthcare-billing, patient-payments, saas, drip-company-fix, rcm-consolidation, health-systems, dsos, urgent-care, waystar-competition, phreesia-rivalry, ai-bill-explainer, health-plan-licensing, smb-healthcare, revenue-cycle-management, denial-management, patient-engagement, fintech-healthcare, health-plan-partnerships, revspring-integration